Surge in Drug Prices Tied to Revenue, Million-Dollar Bonuses

(Bloomberg) -- The price of Celgene Corp’s cancer treatment Revlimid, the second best seller among U.S. drugs, more than tripled since 2005 to $719 per pill as company executives pushed to meet rev...